In an early report on this study, Huang et al. showed that 8 of 27 treated patients exhibited a complete response or major pathological response after neoadjuvant therapy: these rapid clinical responses were associated with the accumulation of exhausted CD8+ cells in the tumor at 3 weeks. This evidence concerns the gene CD8A and neoplasm.